Literature DB >> 11677281

Mutagen sensitivity and p53 expression in colorectal cancer in China.

L Shao1, M Lai, Q Huang.   

Abstract

OBJECTIVE: This study was designed to investigate DNA damage and/or repair capability, non-random chromatid breakage, and p53 expression in patients with colorectal cancer.
METHODS: The bleomycin sensitivity assay was used in a case-control study to compare the DNA damage repair system between colorectal cancer patients and controls. G-banding was used to search for non-random chromatid breaks. Immunocytochemistry was used to investigate p53 expression in tumour tissues and adjacent normal tissues.
RESULTS: It was found that cases typically had a higher number of chromosome breaks than controls (0.84 v 0.69 breaks/cell, p<0.01). After correction by sex and age, the difference was still significant (F=4.38, p<0.05). The correlation coefficient between mutagen sensitivity and age was 0.31(p<0.05) in controls and 0.18 (p>0.05) in cases. The ratio of odds ratios among bleomycin resistant, sensitive, and hypersensitive classes was 1:2.31:3.85. Overexpression of p53 was detected in 25 of 47 tumour tissues independent of tumour stage. Cases who had a family history of cancer were susceptible to the p53 aberration (p<0.05). Chromosomes 1p, 5q, and 14q were susceptible to breakage in patients with colorectal cancer.
CONCLUSION: Patients with colorectal cancer show increased bleomycin induced chromatid breaks and may have minor DNA repair deficiencies. p53 aberration is an early event in the development of colorectal cancer, but no definite correlation is found between p53 overexpression and mutagen sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677281      PMCID: PMC1742176          DOI: 10.1136/pmj.77.913.713

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  20 in total

Review 1.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

2.  p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas.

Authors:  I B Gimenez-Conti; A M Collet; H Lanfranchi; M E Itoiz; M Luna; H J Xu; S X Hu; W F Benedict; C J Conti
Journal:  Cancer       Date:  1996-07-01       Impact factor: 6.860

3.  Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer.

Authors:  U Kressner; G Lindmark; B Gerdin; L Påhlman; B Glimelius
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

4.  p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence.

Authors:  H Hasegawa; M Ueda; K Furukawa; M Watanabe; T Teramoto; M Mukai; M Kitajima
Journal:  Int J Cancer       Date:  1995-02-20       Impact factor: 7.396

5.  Genetic susceptibility to head and neck squamous cell carcinoma.

Authors:  J Cloos; M R Spitz; S P Schantz; T C Hsu; Z F Zhang; H Tobi; B J Braakhuis; G B Snow
Journal:  J Natl Cancer Inst       Date:  1996-04-17       Impact factor: 13.506

6.  A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases.

Authors:  X Wu; T C Hsu; J F Annegers; C I Amos; J J Fueger; M R Spitz
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

7.  Chromosome sensitivity to bleomycin-induced mutagenesis in lymphocytes from colorectal cancer patients under 40 years of age.

Authors:  Z Fireman; F Shabtai; B Lurie
Journal:  Dis Colon Rectum       Date:  1994-12       Impact factor: 4.585

8.  Mutagen sensitivity as a marker of cancer risk.

Authors:  M R Spitz; T C Hsu
Journal:  Cancer Detect Prev       Date:  1994

9.  Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck.

Authors:  J K Field; D A Spandidos; A Malliri; J R Gosney; M Yiagnisis; P M Stell
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

10.  p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies.

Authors:  O Gallo; S Bianchi; M L Giovannucci-Uzzielli; R Santoro; S Lenzi; C Salimbeni; M Abbruzzese; E Alajmo
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.